EP4274896A1 — Complement component 9 (c9) irna compositions and methods of use thereof
Assigned to Alnylam Pharmaceuticals Inc · Expires 2023-11-15 · 3y expired
What this patent protects
The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component 9 (C9) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a C9 gene and to methods of preventing and treating…
USPTO Abstract
The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component 9 (C9) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a C9 gene and to methods of preventing and treating a C9-associated disorder, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.